BioNexus Gene Lab pricied of its public offering of 1.25M shares of common stock at a price of $4.00 per share. Network 1 Financial Securities is acting as the sole book-running manager for the offering. BioNexus is developing non-invasive liquid biopsy tests for the early detection of disease risks in the Southeast Asia region.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BGLC: